Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than conventional PCI. However, in many cases, stenting is required to treat suboptimal results. Even though several studies have looked into this scenario, long term durability still calls for research. This was a 5 year thorough analysis of the<a href="https://solaci.org/en/2024/03/09/in-pact-outcomes-at-5-years/" title="Read more" >...</a>
The use of drug-covered balloons (DCBs) has increased significantly for the endovascular treatment of femoropopliteal arterial disease. Previous studies on first-generation high-dose DCB (HD-DCB) have validated its benefits, thus supporting its recommendation in current clinical guidelines. However, there have been reports of adverse effects associated with paclitaxel and its excipients. Second-generation, lower-dose DCBs (LD-DCB) have<a href="https://solaci.org/en/2024/03/01/treatment-of-femoropopliteal-lesions-with-low-dose-vs-high-dose-drug-coated-balloons/" title="Read more" >...</a>
In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and<a href="https://solaci.org/en/2024/02/22/recurrent-revascularization-at-10-years-after-percutaneous-treatment-of-des-in-stent-restenosis/" title="Read more" >...</a>
Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this strategy have shown clinical outcomes comparable to drug-eluting stents’ (DES) in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCB in large coronary vessels is limited. This observational, retrospective study DCB<a href="https://solaci.org/en/2023/12/21/outcomes-of-the-use-of-drug-coated-balloons-in-the-treatment-of-de-novo-coronary-lesions/" title="Read more" >...</a>
There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity<a href="https://solaci.org/en/2023/11/30/low-gradient-normal-flow-aortic-stenosis-changes-in-quality-of-life-with-tavr/" title="Read more" >...</a>
Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents a significant challenge involving a high incidence of major adverse cardiovascular events (MACE). Rotational atherectomy (RA) is used to modify these calcified lesions and facilitate balloon angioplasty followed by stent implantation. The combination of RA with other plaque<a href="https://solaci.org/en/2023/11/30/rotacut-study-rotational-atherectomy-with-cutting-balloon-for-stent-expansion-optimization/" title="Read more" >...</a>
The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding. However, researchers are also looking into another strategy to<a href="https://solaci.org/en/2023/11/22/stentless-strategy-in-acs-perfusion-and-drug-coated-balloons/" title="Read more" >...</a>
The use of drub coated balloons (DCB) in the treatment of femoropopliteal artery disease has grown. Studies on first generation high dose DCB (HD-DCB) have shown benefits, which has led to their recommendation by current guidelines. However, there have been reports of secondary effects caused by paclitaxel and its excipients. Second generation low dose DCB<a href="https://solaci.org/en/2023/11/02/low-vs-high-dose-drug-coated-balloons-in-femoropopliteal-territory/" title="Read more" >...</a>
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at<a href="https://solaci.org/en/2023/10/30/tct-2023-compare-60-80-hbr-trial-2/" title="Read more" >...</a>
Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients. The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total<a href="https://solaci.org/en/2023/10/19/ultrathin-stents-shown-safe-and-effective-in-real-world-patients/" title="Read more" >...</a>